Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Research Abstract |
In light of the absence of a prophylactic vaccine, therapeutic strategies that reduce sexual transmission of HIV are urgently needed. In this study, we evaluated whether exposure of semen collected after oral administration of Maraviroc (MVC), which is a orally available antagonist for CCR5 and has been clinically used for AIDS therapy, demonstrated potent blocking effect for HIV infection or not. We evaluated by using an ex vivo skin explant model. Even if volunteers were orally administrated MVC (600mg/day) for 1, 2, 3, or 14 days and then semen was collected, exposure of semen to epidermal sheets obtained from another volunteers had not significant blocking effect for HIV infection in epidermal LCs.
|